News & Comment

Halozyme has developed ENHANZE, a recombinant human hyaluronidase-based drug delivery technology that enables and optimizes subcutaneous drug delivery for appropriate coadministered therapeutics.

BioMarker Strategies has developed an innovative approach to enable more accurate prediction of patient response to targeted treatments for solid tumors.

BioMarker Strategies has developed an innovative approach to enable more accurate prediction of patient response to targeted treatments for solid tumors.

LYFE Capital, based in Shanghai with a US office in Palo Alto, California, is a healthcare investment firm that targets biopharma, medtech, healthcare service and digital health companies.

The National Institutes of Health (NIH) is the world’s largest collection of biomedical research institutions and a global translational powerhouse. The National Cancer Institute’s Technology Transfer Center, through its expertise in managing the commercialization of its own and nine other NIH institutes’ discoveries, is leading the way for those seeking to partner and develop world-class biomedical solutions.

In just four years, Cinfa Biotech’s pegfilgrastim biosimilar has been developed, been tested, and received acceptance from the European Medicines Agency for review of a marketing authorization application to treat neutropenia.

In just four years, Cinfa Biotech’s pegfilgrastim biosimilar has been developed, been tested, and received acceptance from the European Medicines Agency for review of a marketing authorization application to treat neutropenia.

Promethera Biosciences is developing cell-based therapies to treat major acute and chronic liver diseases. Building on its research into immunomodulatory and antifibrotic allogeneic therapies, the biotech is running clinical development programs in acute-on-chronic liver failure (ACLF) and nonalcoholic steatohepatitis (NASH).

Inflammation – it’s a term that conjures up two very different scenarios in the body: one that is vital to healing and another that can lead to chronic inflammatory diseases. Inflammation, at its best, is the part of the body’s fight response where it rushes blood, fluid and proteins to an impacted area to create swelling and heat to protect, repair and heal. In the second scenario, when this carefully regulated system goes awry and inflammation in the body becomes chronic and systemic, it can lead to a growing list of cardiovascular and autoimmune diseases including heart disease, stroke, peripheral vascular disease, rheumatoid arthritis (RA), Crohn’s disease and multiple sclerosis (MS). While medical devices have not historically played a role in treating inflammatory diseases, that is changing due to the fast-growing field of bioelectronic medicine.

Technology-focused life science fund Efung Capital is riding the wave of China’s increase in medical investment and demand for healthcare products and services.

Inadequate or unsuitable intellectual property (IP) protection could allow competitors to more easily launch a competing product, jeopardizing the opportunity for meaningful return on investment and consequently potential dealmaking. This feature discusses key factors for biotechnology companies to consider in creating IP strategies to support value.

Are you a scientist-entrepreneur with an outstanding start-up company based on scientific research? Or a university or research institution looking to showcase your most promising academic spin‑off?

Parkway Pantai, one of Asia’s largest private healthcare providers, has brought precision medicine into its integrated suite of healthcare services.

SkylineDx is using its expertise to bridge the gap between novel gene expression signatures and commercially available diagnostic products with high clinical utility.

Arquer Diagnostics is developing a series of innovative, non-invasive tests for cancer and recently launched ADXBLADDER, a reliable urine test for bladder cancer.

Karius has developed a cell-free-DNA-based diagnostic test capable of identifying bacteria, mycobacteria, DNA viruses, fungi and protozoa in the blood down to the species level, thereby rapidly improving the diagnosis of infectious diseases.

Andarix Pharmaceuticals is a clinical-stage company that develops highly specific radiolabeled peptides for targeted radiotherapy and diagnostic imaging in cancer.

Pacific Edge’s state-of-the-art suite of bladder cancer detection and management tests are noninvasive, highly effective, and more accurate than other urine-based cancer diagnostic tests, and are now being adopted into the standard of care.

With its innovative bone graft scaffold, GreenBone Ortho srl is well on its way to becoming a worldwide leader in bone regeneration.

Targeting a largely unmet and potentially billion-dollar market, SnooZeal is developing a clinically proven daytime treatment for snoring and sleep apnea.